Antibiotic treatment issues in patients with COVID-19

Czech version

Authors: Milan Kolář ¹; Lenka Doubravská ²; Petr Jakubec ³; Miroslava Htoutou Sedláková ¹; Kateřina Fišerová ¹
Authors‘ workplace: Ústav mikrobiologie, Fakultní nemocnice Olomouc ¹; Klinika anesteziologie, resuscitace a intenzivní medicíny, Fakultní nemocnice Olomouc ²; Klinika plicních nemocí a tuberkulózy, Fakultní nemocnice Olomouc ³
Published in: Vnitř Lék 2021; 67(8): 448-454
Category: Review Articles

Overview

The COVID-19 pandemic may increase the current threat of antimicrobial resistance and exacerbate another, rather silent, pandemic posed by the increasing frequency of multidrug-resistant bacterial pathogens and the associated potential for loss of effective antibiotics. Antibiotic treatment has often been used in patients hospitalized for COVID-19 due to concerns about possible bacterial co-infection, as confirmed by previous experience with viral respiratory infections such as H1N1 influenza, SARS and MERS. Concerns or unknowns related to the COVID-19 pandemic have also affected physicians‘ behavior, including the use of antibiotics. However, the high rate of antibiotic use in patients, especially those with mild to moderate COVID-19 disease, is inconsistent with the actual incidence of bacterial co-infections and/or secondary respiratory infections. Thus, it is clear that a careful assessment of the role of antibiotic treatment in patients hospitalized for COVID-19 is required. According to the current WHO recommendation, the application of antibiotics is especially suitable for patients with severe/critical degree of respiratory insufficiency requiring intensive oxygen therapy, artificial lung ventilation or support by extracorporeal membrane oxygenation.

Keywords:

Bacteria – COVID-19 – pneumonia – antibiotics

Sources

1. Rice TW, Rubinson L, Uyeki TM et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med 2012; 40(5): 1487–1498. Dostupné z DOI: <https://doi.org/10.1097/CCM.0b013e3182416f23>.

2. Shah NS, Greenberg JA, McNulty MC et al. Bacterial and viral co‑infections complicating severe influenza: Incidence and impact among 507 U.S. patients, 2013–2014. J Clin Virol 2016; 80: 12–19. Dostupné z DOI: <https://doi.org/10.1016/j.jcv.2016. 04. 008>.

3. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis 2019; 68(6): e1–e47. Dostupné z DOI: <https://doi.org/10.1093/cid/ciy866>.

4. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054–1062. Dostupné z DOI: <https://doi.org/10.1016/S0140-6736(20)30566-3>.

5. Arshad S, Kilgore P, Chaudhry ZS et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis 2020; 97: 396– 403. Dostupné z DOI: <https://doi.org/10.1016/j.ijid.2020. 06. 099>.

6. Chen J, Liu D, Liu L et al. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2020; 49(2): 215–219. Dostupné z DOI: <https://doi.org/10.3785/j.issn.1008-9292.2020. 03. 03>.

7. Gautret P, Lagier JC, Parola P et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open‑label non‑randomized clinical trial. Int J Antimicrob Agents 2020; 56(1): 105949. Dostupné z DOI: <https://doi.org/10.1016/j.ijantimicag.2020.105949>.

8. Yang X, Yu Y, Xu J et al. Clinical course and outcomes of critically ill patients with SARS‑CoV- 2 pneumonia in Wuhan, China: a single‑centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5): 475–481. Dostupné z DOI: <https://doi.org/10.1016/S2213-2600(20)30079-5>.

9. Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507–513. Dostupné z DOI: < https://doi.org/10.1016/S0140-6736(20)30211-7>.

10. Nori P, Cowman K, Chen V, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infect Control Hosp Epidemiol 2021; 42(1): 84–88. Dostupné z DOI: <https://doi.org/10.1017/ice.2020.368>.

11. Lansbury L, Lim B, Baskaran V, Lim WS. Co‑infections in people with COVID-19: a systematic review and meta‑analysis. J Infect 2020; 81(2): 266–275. Dostupné z DOI: < https://doi.org/ 10.1016/j.jinf.2020. 05. 046>.

12. Vaughn VM, Gandhi T, Petty LA et al. Empiric Antibacterial Therapy and Community‑onset Bacterial Co‑infection in Patients Hospitalized with COVID-19: A Multi‑Hospital Cohort Study. Clin Infect Dis 2021; 72(10): e533–e541. Dostupné z DOI: < https://doi.org/10.1093/cid/ciaa1239>.

13. Buetti N, Mazzuchelli T, Lo Priore E et al. Early administered antibiotics do not impact mortality in critically ill patients with COVID-19. J Infect 2020; 81(2): e148–e149. Dostupné z DOI: <https://doi.org/10.1016/j.jinf.2020. 06. 004>.

14. Garcia‑Vidal C, Sanjuan G, Moreno‑García E et al. Incidence of co‑infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect 2021; 27(1): 83–88. Dostupné z DOI: < https://doi.org/10.1016/j.cmi.2020. 07. 041>.

15. Chedid M, Waked R, Haddad E et al. Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. J Infect Public Health 2021; 14(5): 570–576. Dostupné z DOI: < https://doi.org/10.1016/j.jiph.2021. 02. 001>.

16. Wang D, Hu B, Hu C et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061–1069. Dopstupné z DOI: <https://doi.org/10.1001/jama.2020.1585>.

17. Wang D, Yin Y, Hu C et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS‑CoV- 2, discharged from two hospitals in Wuhan, China. Crit Care 2020; 24(1): 188. Dostupné z DOI: < https://doi.org/10.1186/s13054-020-02895-6>.

18. Wang Z, Yang B, Li Q et al. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis 2020; 71(15): 769–777. Dostupné z DOI: <https://doi.org/10.1093/cid/ciaa272>.

19. He Y, Li W, Wang Z, et al. Nosocomial infection among patients with COVID-19: a retrospective data analysis of 918 cases from a single center in Wuhan, China. Infect Control Hosp Epidemiol 2020; 41(8): 982–983. Dostupné z DOI: <https://doi.org/10.1017/ice.2020.126>.

20. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497–506. Dostupné z DOI: <https://doi.org/10.1016/S0140-6736(20)30183-5>.

21. Chen G, Wu D, Guo W et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130(5): 2620–2629. Dostupné z DOI: <https://doi.org/10.1172/JCI137244>.

22. Chen T, Wu D, Chen H et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368: m1295. Dostupné z DOI: <https://doi.org/10.1136/bmj.m1295>.

23. Chen H, Guo J, Wang C et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records Lancet 2020; 395 (10226): 809–815. Dostupné z DOI: <https://doi.org/10.1016/S0140-6736(20)30360-3>.

24. Xu XW, Wu XX, Jiang XG et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS‑Cov- 2) outside of Wuhan, China: retrospective case series. BMJ 2020; 368: m606. Dostupné z DOI: <https://doi.org/10.1136/bmj.m606>.

25. Cao B, Wang Y, Wen D et al. A trial of Lopinavir–Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382(19): 1787–1799. Dostupné z DOI: <https://doi.org/10.1056/NEJMoa2001282>.

26. Zhao XY, Xu XX, Yin HS et al. Clinical characteristics of patients with 2019 coronavirus disease in a non‑Wuhan area of Hubei Province, China: a retrospective study. BMC Infect Dis 2020; 20(1): 311. Dostupné z DOI: <https://doi.org/10.1186/s12879-020-05010-w>.

27. Borba MGS, Val FFA, Sampaio VS et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS‑CoV- 2) infection: a randomized clinical trial. JAMA Netw Open 2020; 3(4): e208857. Dostupné z DOI: <https://doi.org/10.1001/jamanetworkopen.2020.8857>.

28. Pedersen HP, Hildebrandt T, Poulsen A, et al. Initial experiences from patients with COVID- 19 on ventilatory support in Denmark. Dan Med J 2020; 67(5): A04200232. PMID: 32351196.

29. Aggarwal S, Garcia‑Telles N, Aggarwal G et al. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States. Diagnosis 2020; 7(2): 91–96. Dostupné z DOI: <https://doi.org/10.1515/dx-2020-0046>.

30. Guan W, Ni Z, Hu Y et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382(18): 1708–1720. Dostupné z DOI: <https://doi.org/10.1056/NEJMoa2002032>.

31. Htoutou Sedláková M, Vojtová V, Hanulík V, et al. Rezistence enterobakterií k vybraným antibiotikům v souvislosti s jejich spotřebou. Klin Farmakol Farm 2012; 26(2): 61–66.

32. Urbanek K, Kolar M, Loveckova Y et al. Influence of 3rd generation cephalosporin utilization on the occurrence of ESBL‑positive Klebsiella pneumoniae strains. J Clin Pharm Ther 2007; 32(4): 403–408. Dostupné z DOI: <https://doi.org/10.1111/j.1365-2710.2007.00836.x>.

33. Kolar M, Urbanek K, Latal T. Antibiotic selective pressure and development of bacterial resistance. Int J Antimicrob Agents 2001; 17(5): 357–363. Dostupné z DOI: <https://doi.org/10.1016/s0924-8579(01)00317-x>.

34. Kim HS. Do an altered gut microbiota and an associated leaky gut affect COVID-19 severity? mBio 2021; 12 (1): e03022-20. Dostupné z DOI: <https://doi.org/10.1128/mBio.03022-20>.

35. Martin E, Philbin M, Hughes G et al. Antimicrobial stewardship challenges and innovative initiatives in the acute hospital setting during the COVID-19 pandemic. J Antimicrob Chemother 2021; 76(1): 272–275. Dostupné z DOI: <https://doi.org/10.1093/jac/dkaa400>.

36. Sieswerda E, De Boer MGJ, Bonten MM et al. Recommendations for antibacterial therapy in adults with COVID-19 – An evidence based guideline. Clin Microbiol Infect 2021; 27(1): 61–66. Dostupné z DOI: <https://doi.org/10.1016/j.cmi.2020. 09. 041>.

37. World Health Organization. COVID-19 Clinical management: living guidance. WHO. [cit. 2021-09-01]. Dostupné z WWW: <https://www.who.int/publications/i/item/WHO-2019-nCoV‑clinical-2021-1>.

38. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID- 19. NICE. [cit. 2021-09-01]. Dostupné z WWW: <https://www.nice.org.uk/guidance/ng191>.

39. Cong W, Poudel AN, Alhusein N et al. Antimicrobial Use in COVID-19 Patients in the First Phase of the SARS‑CoV- 2 Pandemic: A Scoping Review. Antibiotics 2021; 10(6): 745. Dostupné z DOI: <https://doi.org/10.3390/antibiotics10060745>.

40. Liu C, Wen Y, Wan W et al. Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19. Int Immunopharmacol 2021; 90: 107157. Dostupné z DOI: <https://doi.org/10.1016/j.intimp.2020.107157>.

41. Kolář M. Respirační infekce a jejich léčba. Maxdorf: Praha 2016. ISBN 978-80-7345-481-4.

42. Kolář M, Bardoň J, Rejman D. Zásady antibiotické léčby. VUP: Olomouc 2020. ISBN 978-80-244-5740-6.

43. Kolář M, Beneš J, Kolek V, et al. Klinický doporučený postup Nozokomiální pneumonie – antibiotická léčba. Národní portál klinických doporučených postupů [cit. 2021-09-01]. Dostupné z WWW: <https://kdp.uzis.cz>.

44. Torres A, Niederman M, Chastre J et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital‑acquired pneumonia and ventilator‑associated pneumonia. Eur Respir J 2017; 50(3): 1700582. Dostupné z DOI: <https://doi.org/10.1183/13993003.00582-2017>.

Labels

Diabetology Endocrinology Internal medicine

Acute searching and early diagnosis of HCV infected persons

Optimal potassium levels in patients with heart failure

Unicentric Castleman’s disease. Symptoms, diagnostics and therapy

SGLT2 inhibitors – a new pillar for the treatment of heart failure

Renal parenchymal hypertension: relevant new aspects

Bilateral multiple pneumatocele as a rare late complication of COVID-19 pneumonia

What are the specifics of diabetic foot syndrome and why we need interdisciplinary recommendations for its diagnosis and treatment?

Expert consensus on the importance of iron deficiency and the possibility of its correction in patients with heart failure

Memorandum z jednání zástupců ČIS a ČPFS dne 6. 5. 2021 v Lékařském domě ČLS JEP v Praze

Article was published in

Internal Medicine

2021 Issue 8